U.S. Meniere’s Disease Drug Market, By Type (Classic, Bilateral, Vestibular), Treatment (Drug, Surgical, Suplemental Therapies & Procedure), Drug Type (Generics, Branded), Route of Administration (Oral, Parenteral), End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) – Industry Trends and Forecast to 2030.
U.S. Meniere’s Disease Drug Market Analysis and Size
Rising number of meniere’s disease drugs as compared to the last few years will incease the market growth. As per the National Institute on Deafness and Other Communication Disorders, about 615,000 people in the U.S. have Meniere's disease. Rigorous regulation protocols by regulatory authorities is hindering the meniere’s disease drugs market that further creates new opportunities for the market.
Data Bridge Market Research analyses a growth rate in the meniere’s disease drug market in the forecast period 2023-2030. The expected CAGR of meniere’s disease drug market is tend to be around 4.4% in the mentioned forecast period. The market value is USD 126.5 million in 2022, and it would grow upto USD 178.5 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
U.S. Meniere’s Disease Drug Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Classic, Bilateral, Vestibular), Treatment (Drug, Surgical, Suplemental Therapies & Procedure), Drug Type (Generics, Branded), Route of Administration (Oral, Parenteral),End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
|
|
Market Players Covered
|
Agouron Pharmaceuticals, LLC (U.S.), AHP Holdings B.V. (Netherlands), Alacer Corp. (U.S.), Alpharma Pharmaceuticals LLC (U.S.), Bioren, LLC (U.S.) and G. D. Searle & Co. Limited (U.K.) Hikma Pharmaceuticals PLC (U.K.), Mylan N.V.(U.S.), Pfizer Inc.(U.S.), Fresenius Kabi AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Meniere’s disease is a type of middle ear disorder that leads to ear ringing (tinnitus), vertigo, ear pain and hearing problems. People suffering from Meniere’s disease generally experience these symptoms during sudden episodes, that specifically last around two to three hours. The patient experiences recurrent episodes of vertigo. The vertigo tends to occur less commonly during the later stages, whereas the tinnitus and hearing loss often become worse and the patient may suffer from permanent balance and hearing issues.
U.S. Meniere’s Disease Drug Market Dynamics
Drivers
- Rising Prevalence of Meniere’s Disease
As per the National Institute on Deafness and Other Communication Disorders, around 615,000 people in the U.S. suffer from Meniere's disease. In 2019, Hearing Health Foundation estimated that there are around 600,000-750,000 meniere’s disease cases combined with 45,000 to 60,000 new cases diagnosis in the U.S. Majority of the meniere’s disease cases are unilateral, but then as per the records, 15% to 40% of total patients are affected in both ears. Thus, this boost the growth of the treatment market.
- Increasing Demand of Off label Drugs
Off label drugs lead the largest market share primarily because of the absence of novel therapeutics in the market. Though, some of the companies are conducting huge studies to develop a drug dedicated for the treatment of Meniere disease, the increasing absence of the cause of disease development, makes it a tedious process. Tranquillizers hold the major market share since they are prescribed for vertigo and vomiting, which are the disease's primary symptoms. Thus, this boost the market growth.
Opportunities
- Growing Demand of Vestibular Nerve Segment
The vestibular nerve section surgical procedure opens the internal auditory canal and the procedure is specifically carried out through either a retrosigmoid or a middle fossa approach. The middle fossa approach for vestibular nerve section is technically more difficult. The benefit of the middle fossa approach is that it achieves a relatively more complete ablation of vestibular function compared to the retrosigmoid approach because of the vestibular fibers. The vestibular nerve section has the biggest advantage of a high rate of vertigo control around 95-98% with an increased hearing preservation rate in the operated ear. Thus, this boost the market growth.
- Increasing Advancements in Medicinal & Pharmacy Therapeutics
Huge advancements in medicinal and pharmacy therapeutics related with Meniere’s diseases are pushing the Meniere’s disease treatment market. Increasing use of injectable and surgical procedures is being used regularly for the treatment of patients suffering from Meniere’s diseases. Thus, these factors are anticipated to fuel the Meniere’s disease treatment market during the forecast period 2023-2030. Thus, this leads to the growth of the market.
Restraints/Challenges
- Side-Effects of Diagnostics and Treatment Methods of Meniere’s Disease
There are various side-effects that are associated with the disease such as dizziness, nausea or headache. Furthermore, diagnostic procedures such as vestibular evoked myogenic potential sound stimulation can lead to noise-induced hearing loss in many cases with high sensitivity to noise exposure or by surpassing individual cochlear safety thresholds. Thus, these factors restrict the market growth.
This meniere’s disease drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the meniere’s disease drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
U.S. Meniere’s Disease Drug Market Scope
The meniere’s disease drug market is segmented on the basis of type, treatment, drug type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Classic
- Bilateral
- Vestibular
Treatment
- Drug
- Short-term medications
- Long-term medications
- Injectable medications
- Surgical
- Endolymphatic sac
- Vestibular nerve section
- Labyrinthectomy
- Suplemental Therapies & Procedure
- Vestibular rehabilitation
- Hearing aid
- Meniett pulse generator
Drug Type
- Generic
- Branded
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Others
Distribution Channel
- Direct Tender
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Competitive Landscape and U.S. Meniere’s Disease Drug Market Share Analysis
The meniere’s disease drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, U.S. presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to meniere’s disease drug market.
Key players operating in the meniere’s disease drug market include:
- Agouron Pharmaceuticals, LLC (U.S.)
- AHP Holdings B.V. (Netherlands)
- Alacer Corp. (U.S.)
- Alpharma Pharmaceuticals LLC (U.S.)
- Bioren, LLC (U.S.)
- G. D. Searle & Co. Limited (U.K.)
- Hikma Pharmaceuticals PLC (U.K.)
- Mylan N.V.(U.S.)
- Pfizer Inc. (U.S.)
- Fresenius Kabi AG (Germany)
- F. Hoffmann-La Roche Ltd. (Switzerland)
SKU-